BioCentury
ARTICLE | Clinical News

Tracleer bosentan: Phase III expanded

July 28, 2008 7:00 AM UTC

Actelion expanded enrollment in the double-blind, placebo-controlled, international, Phase III BUILD-3 trial to around 600 patients. The company said the original target enrollment of 390 patients had...